Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

VCA Antech Q4 Loss Widens; Provides FY13 Outlook - Quick Facts

RELATED NEWS
Trade WOOF now with 

VCA Antech Inc. (WOOF: Quote) reported that its fourth-quarter net loss attributable to the company was $58.1 million or $0.66 per share, wider than $3.2 million or $0.04 per share in the same quarter last year.

Adjusted income attributable to the company for the latest fourth quarter was $21.2 million or $0.24 per share, up from $18.1 million or $0.21 per share in the comparable quarter last year.

On average, eleven analysts polled by Thomson Reuters expected the company to report earnings of $0.24 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter rose to $418.19 million from $369.01 million in the prior year quarter, while nine analysts had consensus revenue estimate of $416.78 million for the quarter.

Looking ahead to fiscal 2013, the company expects net income in the range of $130 million to $139 million or $1.45 per share to $1.55 per share. The company expects revenues from $1.83 billion to $1.86 billion. Analysts currently expect fiscal 2013 earnings of $1.50 per share and revenues of $1.82 billion.

Click here to receive FREE breaking news email alerts for VCA Antech and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.